30 results
8-K
EX-2.1
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
) as required by applicable Law, (iv) in connection with the COVID-19 pandemic, to the extent reasonably necessary, (A) to protect the health and safety … of the Company’s or any of its Subsidiaries’ employees, (B) to respond to third party supply or service disruptions caused by the COVID-19 pandemic
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
of preclinical and clinical studies may not be predictive of future results; and the risk that the COVID-19 worldwide pandemic may negatively impact
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
; and the risk that the COVID-19 worldwide pandemic may negatively impact the Company’s business, operations, clinical trials or ability to raise
424B5
STSA
Satsuma Pharmaceuticals Inc
3 Nov 22
Prospectus supplement for primary offering
4:42pm
trials and timing of expected data announcements;
the impacts of the COVID-19 pandemic on our operations;
the timing of commencement of future
8-K
EX-99.1
agcrs0x24 ttdr7by
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
EX-99.1
i1c38
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm
8-K
EX-99.1
513yqg5kvkxmu
10 May 22
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results
4:02pm
8-K
EX-99.1
euehgps5up9dmg
15 Mar 22
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
4:40pm
8-K
EX-99.1
bdo7 msjxh7aa7k
9 Nov 21
Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:00pm
8-K
EX-99.1
3whu7o
10 Aug 21
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:01pm
8-K
EX-99.1
2mie6j6z
16 Jun 21
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
4:29pm
8-K
EX-99.1
62r9oejhowy4qxjm
11 May 21
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results
4:05pm